ARTL News & Events

Artelo Biosciences announced the publication of a peer-reviewed article titled "Evaluating fatty acid-binding protein 5 as a therapeutic target for pain management" in the European Journal of Pain, an internationally recognized journal in pain research. The article discusses preclinical evidence showing that FABP5 inhibition produced analgesic effects across multiple pain models, including visceral, inflammatory, neuropathic, and joint pain. The publication also highlights evidence that FABP5 inhibition may influence several established pain-related pathways while reducing pro-inflammatory mediators, supporting its potential as a differentiated, non-opioid therapeutic approach. These findings are supported by a broader body of evidence - specifically for ART26.12 - from seven prior preclinical studies in diabetic neuropathy, osteoarthritis, cancer bone pain, and peripheral neuropathy caused by chemotherapy. ART26.12 demonstrated consistent analgesic activity across each model and validated FABP5 as a novel lipid-signaling target for pain treatment.

Artelo Biosciences files to sell 9.82M shares of common stock for holders

Artelo Biosciences announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 3,188,407 shares of common stock and warrants to purchase up to 6,376,814 shares of common stock, at a combined purchase price of $3.45 per share of common stock and accompanying warrants, in a private placement priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $3.20 per share, will be exercisable upon issuance and will expire five and one-half years from the Effectiveness Date. The private placement is expected to close on or about March 30, 2026, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds from the offering are expected to be approximately $11M, prior to deducting placement agent fees and other offering expenses payable by the company. The company intends to use the net proceeds from the offering for working capital, general corporate purposes, and the repayment of certain bridge debt. The potential additional gross proceeds to the company from the warrants, if fully exercised on a cash basis, will be approximately $20.4M. No assurance can be given that any of the warrants will be exercised, or that the company will receive cash proceeds from the exercise of the warrants.